MARKET

KAPA

KAPA

KAIROS PHARMA LTD
AMEX
0.9093
+0.0643
+7.61%
After Hours: 0.9200 +0.0107 +1.18% 17:21 12/04 EST
OPEN
0.8400
PREV CLOSE
0.8450
HIGH
0.9200
LOW
0.7960
VOLUME
96.96K
TURNOVER
--
52 WEEK HIGH
3.250
52 WEEK LOW
0.4000
MARKET CAP
18.93M
P/E (TTM)
-2.9862
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KAPA last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at KAPA last week (1117-1121)?
Weekly Report · 11/24 10:17
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
TipRanks · 11/19 16:55
Kairos Pharma Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/19 13:19
Kairos Pharma Price Target Maintained With a $9.00/Share by D. Boral Capital
Dow Jones · 11/19 13:19
D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
Benzinga · 11/19 13:09
Weekly Report: what happened at KAPA last week (1110-1114)?
Weekly Report · 11/17 10:17
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 11/11 21:07
More
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

Webull offers Kairos Pharma Ltd stock information, including AMEX: KAPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KAPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KAPA stock methods without spending real money on the virtual paper trading platform.